Mass spectrometry-based identification of ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies.
Auteur(s) :
Vulsteke, Jean-Baptiste [Auteur]
Derua, Rita [Auteur]
Catholic University of Leuven = Katholieke Universiteit Leuven [KU Leuven]
Dubucquoi, Sylvain [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Coutant, Frédéric [Auteur]
Hospices Civils de Lyon [HCL]
Sanges, Sebastien [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Lille Inflammation Research International Center (LIRIC) - U995
Goncalves, David [Auteur]
Hospices Civils de Lyon [HCL]
Wuyts, Greet [Auteur]
De Haes, Petra [Auteur]
Blockmans, Daniel [Auteur]
Wuyts, Wim A. [Auteur]
Claeys, Kristl G. [Auteur]
De Langhe, Ellen [Auteur]
Fabien, Nicole [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Bossuyt, Xavier [Auteur]
Derua, Rita [Auteur]
Catholic University of Leuven = Katholieke Universiteit Leuven [KU Leuven]
Dubucquoi, Sylvain [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Coutant, Frédéric [Auteur]
Hospices Civils de Lyon [HCL]
Sanges, Sebastien [Auteur]
Centre National de Référence des Maladies Auto-Immunes Systémiques Rares du Nord et Nord-Ouest de France [CeRAINO]
Lille Inflammation Research International Center (LIRIC) - U995
Goncalves, David [Auteur]
Hospices Civils de Lyon [HCL]
Wuyts, Greet [Auteur]
De Haes, Petra [Auteur]
Blockmans, Daniel [Auteur]
Wuyts, Wim A. [Auteur]
Claeys, Kristl G. [Auteur]
De Langhe, Ellen [Auteur]
Fabien, Nicole [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Bossuyt, Xavier [Auteur]
Titre de la revue :
Annals of the Rheumatic Diseases
Nom court de la revue :
Ann Rheum Dis
Numéro :
82
Date de publication :
2022-12-28
ISSN :
1468-2060
Mot(s)-clé(s) en anglais :
Autoimmunity
Autoimmune Diseases
Polymyositis
Autoantibodies
Autoimmune Diseases
Polymyositis
Autoantibodies
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Objectives To discover new and detect known antisynthetase autoantibodies (ASAs) through protein immunoprecipitation combined with gel-free liquid chromatography-tandem mass spectrometry (IP-MS).
Methods IP-MS was ...
Lire la suite >Objectives To discover new and detect known antisynthetase autoantibodies (ASAs) through protein immunoprecipitation combined with gel-free liquid chromatography-tandem mass spectrometry (IP-MS). Methods IP-MS was performed using sera of individuals showing features of antisynthetase syndrome (ASyS) without (n=5) and with (n=12) previously detected ASAs, and healthy controls (n=4). New candidate aminoacyl-tRNA-synthetase (ARS) autoantigens identified through unbiased IP-MS were confirmed by IP-western blot. A targeted IP-MS assay for various ASA specificities was developed and validated with sera of patients with known ASAs (n=16), disease controls (n=20) and healthy controls (n=25). The targeted IP-MS assay was applied in an additional cohort of patients with multiple ASyS features or isolated myositis without previously detected ASAs (n=26). Results Autoantibodies to cytoplasmic cysteinyl-tRNA-synthetase (CARS1) were identified by IP-MS and confirmed by western blot as a new ASA specificity, named anti-Ly, in the serum of a patient with ASyS features. Rare ASAs, such as anti-OJ, anti-Zo and anti-KS, and common ASAs could also be identified by IP-MS. A targeted IP-MS approach for ASA detection was developed and validated. Application of this method in an additional cohort identified an additional patient with anti-OJ autoantibodies that were missed by line and dot immunoassays. Discussion CARS1 is the dominant cognate ARS autoantigen of the newly discovered anti-Ly ASA specificity. Rare and common ASA specificities could be detected by both unbiased and targeted IP-MS. Unbiased and targeted IP-MS are promising methods for discovery and detection of autoantibodies, especially autoantibodies that target complex autoantigens.Lire moins >
Lire la suite >Objectives To discover new and detect known antisynthetase autoantibodies (ASAs) through protein immunoprecipitation combined with gel-free liquid chromatography-tandem mass spectrometry (IP-MS). Methods IP-MS was performed using sera of individuals showing features of antisynthetase syndrome (ASyS) without (n=5) and with (n=12) previously detected ASAs, and healthy controls (n=4). New candidate aminoacyl-tRNA-synthetase (ARS) autoantigens identified through unbiased IP-MS were confirmed by IP-western blot. A targeted IP-MS assay for various ASA specificities was developed and validated with sera of patients with known ASAs (n=16), disease controls (n=20) and healthy controls (n=25). The targeted IP-MS assay was applied in an additional cohort of patients with multiple ASyS features or isolated myositis without previously detected ASAs (n=26). Results Autoantibodies to cytoplasmic cysteinyl-tRNA-synthetase (CARS1) were identified by IP-MS and confirmed by western blot as a new ASA specificity, named anti-Ly, in the serum of a patient with ASyS features. Rare ASAs, such as anti-OJ, anti-Zo and anti-KS, and common ASAs could also be identified by IP-MS. A targeted IP-MS approach for ASA detection was developed and validated. Application of this method in an additional cohort identified an additional patient with anti-OJ autoantibodies that were missed by line and dot immunoassays. Discussion CARS1 is the dominant cognate ARS autoantigen of the newly discovered anti-Ly ASA specificity. Rare and common ASA specificities could be detected by both unbiased and targeted IP-MS. Unbiased and targeted IP-MS are promising methods for discovery and detection of autoantibodies, especially autoantibodies that target complex autoantigens.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-01-11T23:48:54Z
2024-03-26T12:12:18Z
2024-03-26T12:12:18Z